UK markets close in 5 hours 58 minutes
  • FTSE 100

    7,057.94
    +76.96 (+1.10%)
     
  • FTSE 250

    23,740.25
    +128.86 (+0.55%)
     
  • AIM

    1,264.18
    +4.05 (+0.32%)
     
  • GBP/EUR

    1.1619
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.3636
    -0.0028 (-0.21%)
     
  • BTC-GBP

    31,071.30
    -823.53 (-2.58%)
     
  • CMC Crypto 200

    1,054.44
    -9.40 (-0.88%)
     
  • S&P 500

    4,354.19
    -3.54 (-0.08%)
     
  • DOW

    33,919.84
    -50.63 (-0.15%)
     
  • CRUDE OIL

    71.67
    +1.18 (+1.67%)
     
  • GOLD FUTURES

    1,775.60
    -2.60 (-0.15%)
     
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • DAX

    15,447.19
    +98.66 (+0.64%)
     
  • CAC 40

    6,624.81
    +72.08 (+1.10%)
     

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, July 26, 2021--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2021 after the market close on Monday August 9, and will also host a conference call and webcast at 4:30 pm Eastern Time on August 9, 2021.

Monday, August 9th @ 4:30 p.m. ET

Domestic: 877-407-0784

International: 201-689-8560

Conference ID: 13721797

Webcast: http://public.viavid.com/index.php?id=145873

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005727/en/

Contacts

IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
(858) 900-2682
IR@ArcturusRx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting